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Abstract
Introduction As several studies have been conducted to
elicit patients’ preferences for cancer treatment, it is
important to provide an overview and synthesis of these
studies. This study aimed to systematically review discrete
choice experiments (DCEs) about patients’ preferences for
cancer treatment and assessed the relative importance of
outcome, process and cost attributes.
Methods A systematic literature review was conducted
using PubMed and EMBASE to identify all DCEs inves-
tigating patients’ preferences for cancer treatment between
January 2010 and April 2016. Data were extracted using a
predefined extraction sheet, and a reporting quality
assessment was applied to all studies. Attributes were
classified into outcome, process and cost attributes, and
their relative importance was assessed.
Results A total of 28 DCEs were identified. More than half
of the studies (56%) received an aggregate score lower than
4 on the PREFS (Purpose, Respondents, Explanation,
Findings, Significance) 5-point scale. Most attributes were
related to outcome (70%), followed by process (25%) and
cost (5%). Outcome attributes were most often significant
(81%), followed by process (73%) and cost (67%). The
relative importance of outcome attributes was ranked
highest in 82% of the cases where it was included, followed
by cost (43%) and process (12%).
Conclusion This systematic review suggests that attributes
related to cancer treatment outcomes are the most impor-
tant for patients. Process and cost attributes were less often
included in studies but were still (but less) important to
patients in most studies. Clinicians and decision makers
should be aware that attribute importance might be influ-
enced by level selection for that attribute.
Key Points for Decision Makers
Outcome attributes regarding effectiveness and
adverse effects are most often included within
discrete choice experiments in cancer treatment, and
are often considered the most important by patients.
Process and cost attributes, in contrast, are included
less often but are still of importance in most studies.
Clinicians and decision makers should be aware that
patients value not only the outcome but also process
and cost attributes, and aligning care with the
patients’ preferences could lead to improved
adherence to treatment and therefore greater
efficiency.
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As the population ages [1], expenditures are increasing,
particularly in oncology care [2], and the efficient alloca-
tion of scarce resources is a key challenge for both policy
makers and healthcare professionals [3, 4]. Rising expenses
in healthcare give greater importance to the evaluation of
interventions, financing and service delivery, which toge-
ther entail the valuation of healthcare and health outcomes
[3, 5]. In Germany, for instance, a reform of the pharma-
ceutical market (AMNOG [Pharmaceutical Market Reor-
ganisation Act]) has been introduced in order to manage
the costs of pharmaceuticals [6]. At the same time, taking
patient preferences into account is seen as increasingly
important, as patients are the payers and consumers of
health technologies and services [7]. Matching healthcare
policy with patient preferences might lead to the improved
effectiveness of healthcare interventions by, for example,
improving the adoption of and adherence to clinical treat-
ments and public health programmes. Furthermore, those
preferences can be useful in designing and evaluating
healthcare programmes [8].
In order to uncover patients’ preferences, several choi-
ces have to be made with regard to the methods of pref-
erence elicitation. Overall, preference elicitation methods
can be divided into ‘revealed’ and ‘stated’ preference
methods [9]. By using surveys to elicit patient preferences
for characteristics of hypothetical treatments in an experi-
mental framework, stated preference methods enable the
assessment the importance of attributes [9, 10]. In contrast,
revealed patient preferences, which rely on observed data,
are difficult to investigate and thus are rarely used in
healthcare. Among stated preferences methods, discrete
choice experiment (DCE), a specific form of conjoint
analysis, has been used extensively to elicit preferences in
healthcare [12]. A DCE is suitable for assessing the relative
importance of attributes and levels, and for calculating
trade-offs between them. The importance of attributes
always depends on the other attributes included in a DCE
and on the range of levels included for an attribute. The
feasibility of the DCE method has already been investi-
gated by several HTA agencies, including the German
Institute for Quality and Efficiency in Health Care (IQWiG
[Institut fu¨r Qualita¨t und Wirtschaftlichkeit im Gesund-
heitswesen]), and an approval decision supported by data
from a DCE was taken by the US Food and Drug
Administration (FDA) [11–13].
In DCEs, respondents are asked to make choices among
hypothetical alternatives that are described by systemati-
cally varying attribute levels (e.g. extent of drug effec-
tiveness, types of adverse effects or frequency of dosage)
[9, 14, 15]. The identification and selection of attributes
and levels are fundamentally important to obtaining valid
results, and a proper selection and descriptions are required
[8, 15]. Attributes chosen to describe alternatives within
DCEs can be categorised, overall, into three main cate-
gories: (1) outcome attributes such as effectiveness or
adverse effects; (2) process attributes, such as the mode of
administration or involvement in clinical decision-making;
and (3) cost attributes [16]. It is known that health-related
outcomes are important decision criteria for patients,
clinicians, policy makers and payers in medical decision-
making processes [17, 18]. The importance of processes
and costs in healthcare, however, are investigated less often
[16].
Within this research, attention is focused on DCE
studies investigating patients’ preferences for cancer
treatment, as early death and disability caused by cancer
have the highest total economic burden worldwide [2]. The
total economic cost of cancer is estimated to be €126 bil-
lion in the European Union [19]. Overall, cancer is a pro-
gressive disease that can affect every part of the body [20];
by 2012, the burden of cancer had risen to approximately
14 million new cases per year and 8.2 million deaths per
year [21]. Previous reviews of DCEs in oncology have
focused mainly on the methodology, such as experiment
design, estimation procedures and validity of responses
[22], on the treatment application [12], or on the prefer-
ences with regard to cancer screening [23, 24]. To our
knowledge, none of these reviews specifically focused on
cancer treatment or synthesized the importance of out-
come, process and costs attributes. Therefore, this review
was designed to systematically review DCEs eliciting
preferences for alternative cancer treatments, assess their
reporting quality using a checklist, and classify treatment
attributes into outcome, process and cost attributes in order
to assess their relative importance. Therefore, reviewing
and synthesising the importance of levels and attributes in
cancer treatments across studies can provide important
insights into the relative importance of specific levels and
attributes to patients, as well as about the importance of
certain types of attributes (e.g. outcome-, process- or cost-
related) relative to each other. Consideration of patients’
values and preferences in clinical decision-making could
indeed improve treatment adherence and satisfaction and
finally lead to improved efficiency in cancer care [20].
2 Methodology
This research was conducted in line with the Preferred
Reporting Items for Systematic Reviews and Meta-Anal-
yses (PRISMA) Statement [25]. For simplicity, the adopted
PRISMA approach is summarised under four headings:
eligibility criteria (Sect. 2.1), search strategy (Sect. 2.2),
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study identification and selection (Sect. 2.3), and data
extraction and quality appraisal (Sect. 2.4).
2.1 Eligibility Criteria
The methodology of this research builds on previous sys-
tematic reviews of DCEs in health economics by de Bek-
ker-Grob et al. [22] and Clark et al. [12]. Only studies
measuring stated preferences for cancer treatment using
DCEs published between 2010 and April 2016 were
included. A study was considered to be a cancer treatment
study when the goal of the examined intervention was to
cure or considerably prolong the life of patients or to
ensure the best possible quality of life to cancer survivors
[26]. DCEs were included when either cancer patients or
parents of children with cancer participated. Studies using
matching methods, multi-criteria decision methods, adap-
tive conjoint analyses or other preference methods were
excluded, as were studies focusing on the methodology of
stated preference methods and reviews of DCEs. Studies in
languages other than English, German, Dutch or French
were not taken into account.
2.2 Search Strategy
To include all relevant DCEs, a two-stage search process
was conducted: (1) ‘reference searching’; and (2) ‘term
searching’. The combination of different search strate-
gies helped to ensure the internal validity of the review.
In reference searching, references of earlier systematic
reviews of DCEs [12, 22] were examined in order to
identify those related to cancer treatment between 2010
and 2012. For term searching, the MEDLINE and
EMBASE databases were screened to identify studies
between 2010 and April 2016. Screening of both data-
bases is beneficial in order to retrieve as many articles as
possible, since EMBASE provides broader coverage of
European journals [27]. To reduce the risk of missing
relevant sources, a manual search within key journals
and the reference lists of identified articles was also
conducted [28].
Search terms were based on previous reviews of de
Bekker-Grob et al. [22] and Clark et al. [12]. For
MEDLINE searches, respective MeSH terms were used
to ensure the inclusion of all synonyms of DCEs and
additional terms related to cancer treatment; searches
within EMBASE included the search function
‘EMTREE’. In addition to the terms, a combination of
subject terms and free-text terms was included: ‘neo-
plasm’, ‘cancer’, ‘therapeutics’ and ‘treatment’. The full
electronic search strategies for both MEDLINE and
EMBASE are shown in Electronic Supplementary
Material Appendix A.
2.3 Study Identification and Selection
For reliability purposes, the identification and selection of
articles was carried out by two independent reviewers and
contained three stages of screening. The first stage included
screening of titles and abstracts and was based on the
predefined eligibility criteria. In the second stage, selected
articles were screened based on the full text. The third
stage consisted of manual searches of the reference list of
identified articles. In case of discrepancies, consensus was
reached with the help of a third researcher.
2.4 Data Extraction and Reporting Quality
Assessment
Data extraction and reporting quality assessment were
performed in four steps. First, DCEs were systematically
reviewed and study characteristics were summarised in a
spreadsheet. Extracted characteristics included title, author,
year of publication, country, study objective, population,
cancer type and sample size. Second, assessment of the
reporting quality was carried out by two independent
reviewers (DRB and MH or MD) using a checklist. This
checklist merged several items of the ISPOR (International
Society For Pharmacoeconomics and Outcomes Research)
checklist [8], which is an extensive guideline for setting up
good practice conjoint analyses, with items of the 5-item
PREFS (Purpose, Respondents, Explanation, Findings,
Significance) checklist by Joy and colleagues [29]. Items
from the PREFs checklist included a well-defined research
question (purpose), an appropriate data collection instru-
ment (respondent information), methods explained in suf-
ficient detail (explanation), valid results and conclusions
(findings), and appropriate statistical analyses (signifi-
cance) [8, 29]. Each item received a binary score (ac-
ceptable or unacceptable) and an aggregate sum score
(ranging from 0 to 5) was calculated and compared across
studies in order to critically assess the reporting quality. In
case of discrepancies, agreement between researchers was
achieved. In addition, data reporting assessment based on
the ISPOR checklist focused on items regarding ‘current
practice’ in DCE development such as attribute and level
identification, attribute and level selection, labelling, the
average number of attributes and levels in the experiment,
and the mode of survey administration [29].
In the third step, attributes were classified into three
classes (outcome, process and cost) and subclasses (e.g. for
outcome: effectiveness, adverse effects, quality of life). In
case of doubt about the allocation of specific attributes, a
second researcher was consulted. In the fourth and last
step, we estimated the frequency of each attribute, then
assessed if the attribute was significant and finally identi-
fied the most important attribute in each study. A
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categorical attribute was considered significant if at least
one coefficient level was significant (at a 5% level). When
the relative importance was directly available, it was taken
from the study after checking the calculations for correct-
ness. If the relative importance was unavailable, but coef-
ficients for attribute levels were provided, their relative
attribute importance was calculated using the range method
as recently proposed by the ISPOR Conjoint Analysis
Good Research Practices Task Force [30]. Within this
method, the range of attribute-specific levels is calculated
by measuring the difference between the highest and
lowest coefficient for the levels of the respective attribute.
The relative importance is then calculated by dividing the
attribute-specific level range by the sum of all attribute
level ranges. The relative attribute importance calculated
with this method always depends on the levels chosen and
on the other attributes included in the experiment. In case
of studies providing neither relative importance nor coef-
ficients, the first author was contacted to get either relative
importance or coefficients. If no data were provided,
studies were excluded from the relative importance anal-
ysis. As an often used attribute had a higher chance of
being selected as the most important, we compared the
mean relative importance of the most important attributes
per attribute class (outcome, process and cost) across the
studies.
3 Results
Figure 1 provides an overview of the results of the study
selection process. In total, 832 possible records were
identified, from which 62 duplicates were removed. After
title/abstract screening of the remaining 770 records, 718
studies were excluded. In the full-text assessment, another
26 articles were excluded, of which eight were published
before 2010 and already included in the reviews by de
Clark et al. [12] and de Bekker-Grob et al. [22]. Two
additional articles were identified through manual searches
of identified articles and included, resulting in 28 articles
for the analysis.
3.1 Study Characteristics
An overview of the study characteristics is provided in
Table 1. Within the investigated timeframe of this review
(January 2010–April 2016), most studies were published in
2012 (25%) [31–37]. The majority of studies were con-
ducted in North America (n = 13) [33, 34, 38–47] with at
least one study each year since 2010; 2014 was a peak year,
with five published studies. Europe has the second most
publications (n = 11) [31, 35, 48–56], while Asia and
Australia, with two published studies each, make less
common use of DCEs in cancer treatment [32, 36, 57, 58].
Sample sizes ranged from 89 up to 1096 participants,
with an average of 272 participants per study (Table 2).
While all studies gathered preferences of patients, five also
included carers’ preferences or those of healthcare provi-
ders [32, 36, 37, 50, 55]. A majority of the 25 studies (89%)
targeted adult patients [31, 32, 34–36, 38–58], and only
two included children or their parents [33, 37]. Further-
more, two studies focused their research on follow-up after
therapy [49, 58] and one study on psychological care
during the treatment process [32].
3.2 Reporting Quality Assessment
Table 2 includes the reporting quality assessment results,
which are summarised by each letter of the acronym
PREFS. All studies had a well-defined research question
and clearly stated the purpose of the study in relation to
preferences. However, only one study reported on the
differences between responders and non-responders [52].
Methods of assessing preferences were clearly explained in
all studies (96%), with one exception [50]. Just over half of
the studies (52%) included all respondents in the analysis
who at least partially completed the preference questions,
or found that those excluded from analysis did not differ
significantly from those included and were therefore found
to have valid results and conclusions. Of 28 studies, 27
used significance tests to assess preference results. More
than half of the studies (56%) received an aggregate score
of 3 or less, one of which achieved a score of 2.
3.3 Current Practice in Data Generation
3.3.1 Attribute and Level Identification and Selection
A total of 93% of the studies reported methods for attribute
identification [31, 32, 34–40, 42–58]; only two studies
(7%) did not [33, 41]. Findings regarding current practice
in attribute and level generation are summarised in Elec-
tronic Supplementary Material Appendix B. To identify
attributes, most studies relied on a literature review of
existing studies or package inserts (79%)
[31, 32, 35–40, 42, 44, 46–52, 54–56, 58], followed by the
use of qualitative research. In particular, expert interviews
were a common method for attribute selection (57%)
[32, 34, 36–40, 42, 43, 45, 47, 49, 50, 52, 55, 56], while
patient interviews were conducted in 30% of studies
[32, 38, 40, 42, 45, 46, 48, 52, 56, 57]. Decisions made by
the research team or the specific use of patient focus groups
were rare (7%) [32, 40]. Two studies used a pilot study in
order to validate their identified attributes [42, 50].
D. R. Bien et al.
Within level identification, a literature review was the
most commonly used method (44%), followed by expert
interviews (33%). This is in contrast to attribute identifi-
cation, where more studies (n = 8) did not report the
identification of attributes (29%), but 20 studies did report
level identification (71%).
3.3.2 Attribute Labelling and Number of Attributes
and Levels
A total of 32% of the studies showed inconsistency in attri-
bute labelling [33, 37–39, 48, 55], meaning that terms used
for the results of analysis were different from those used
within choice tasks and survey description (e.g. ‘severity of
dehydration’ in the analysis in comparison with ‘need to seek
additional treatment for dehydration’ in the choice task ref-
erence). Different attribute labelling might lead to biased
results as participants may have a different understanding of
the attributes when no consistent definition is provided. For
example, one participant might already seek additional
treatment for mild dehydration while another only seeks
additional treatment for severe dehydration.
The number of included attributes is delineated in
Table 1 and ranges mainly from 4 to 8, although two
studies included 11 attributes [46, 53]. Attributes included
at minimum two levels, with a maximum of 5 levels.
3.3.3 Mode of Survey Administration
Nearly half of the studies (48%) used online questionnaires
followed, in 37% of cases, by self-administered paper
questionnaires. One study offered the possibility of
choosing between an online or paper questionnaire [58].
Only five of the studies conducted face-to-face interviews
(19%) [33, 36, 37, 48, 57], of which one was computer-
assisted [48].
3.4 Classification of Attributes and Relative
Importance
3.4.1 Attribute Classification
Of all the attributes included (n = 168) in the 28 studies,
118 were classified as outcome attributes (70%), followed
by 41 process attributes (25%) and nine cost attributes
(5%). The majority of studies (79%) combined the three
attribute classes (outcome, process, cost) within the anal-




























Records identified through database searching:
Medline: n = 736 
Embase: n = 46
Additional records identified through other sources:
Reviews de Bekker-Grob et al., Clark et al.





Records excluded based on exclusion criteria
n = 718
• 421 focused on cancer screening or were 
not DCE 
• 269 were not cancer related
• 28 focused on methodology or were not 






Full-text articles excluded 
n =  26
• 3 Adaptive Conjoint Analyses
• 10 included only professionals or 
stakeholders
• 8 published before 2010
• 2 focused on design of DCEs
• 2 not DCE
• 1 not treatment
Studies included in 
qualitative synthesis
n = 28
Fig. 1 Flow diagram of study
selection adapted from Moher
et al. [25]. DCE discrete choice
experiment
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Table 1 Study characteristics Item Category All studies (n = 28) [n (%)]






















Physicians/healthcare provider 5 (18)
Othersa 2 (7)
Cancer type of interest Breast 8 (30)
Gastrointestinal stromal tumour 1 (4)
Lung 2 (7)
Lymphoma 1 (4)




Renal cell carcinoma 2 (7)
Thyroid 1 (4)
Combination of different cancer types 7 (25)










DCE discrete choice experiment
a More than one category per study possible
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[38, 45, 54] and three studies included only process attri-
butes (11%) [32, 49, 58]. Electronic Supplementary
Material Appendix C provides an overview of all classified
attributes and corresponding studies.
Outcome ‘Progression-free survival’ was the most often
included attribute regarding the effectiveness of treatment
(n = 8) [31, 34, 36, 43, 45, 48, 54, 57], followed by
‘mortality’ (n = 4) [33, 37, 50, 52]. Most attributes were
categorised regarding adverse effects (81 of 122 outcome
attributes). ‘Nausea and vomiting’, ‘diarrhoea’ and ‘fa-
tigue’ were the most commonly used adverse effects
included in ten studies [31, 34, 37–39, 43–46, 48]. ‘Fever
and infection’ as well as ‘hand–foot syndrome’ were also
common (n = 5) [31, 37, 38, 42, 44]. ‘Quality of life’ was
included in four studies [46, 50, 53, 56]; ‘cosmetic out-
come’ was often used as a synonym for quality of life.
Process ‘Dosage form’ was by far the attribute most
often included regarding the treatment process (n = 11)
[31, 34, 36, 37, 41, 43, 46–48, 51, 53], followed by ‘fre-
quency of dosage’ (n = 8) [33, 42, 43, 49, 52, 55, 56, 58]
and ‘waiting time’ (n = 2) [49, 56].
Cost ‘Out-of-pocket cost’ was included in nine studies
[35, 37, 39, 40, 42, 44, 47, 53, 57]. No other attributes
regarding cost were included.
3.4.2 Significance of Attributes
It was possible to analyse attribute significance based on
significant level coefficients in nearly all studies (86%). In
three of four studies, attribute significance could not be
analysed because no information was provided regarding p-
values or confidence intervals [35, 44, 53]; in the fourth
study the coefficients were not reported [41]. Figure 2
shows how often an attribute was significant and thus
important to patients.
Of all 146 included attributes, 90% had significant level
coefficients and were therefore of importance for patients.
Furthermore, overall analysis of the significance shows that
outcome attributes were most often significant, followed by
process and cost attributes. Of 121 included outcome attributes,
95 were significant (79%). The coefficients for the levels of the
outcome attributes related to adverse effects were more often
significant than those for the outcome attributes effectiveness or
quality of life. Of the coefficients for levels of process attributes,
71% were significant. The number of significant process attri-
butes per subclass was more evenly distributed, with one peak
(mode of administration). Six of nine cost attributes were sig-
nificant (67%), i.e. important to patients.
3.4.3 Relative Importance of Attributes
Nearly 70% (19 of 28) of all studies either directly reported
attribute importance based on the range method or reported
level coefficients, which are needed to calculate relative
attribute importance using the range method. One study
reported neither level coefficients nor attribute weights and
was therefore excluded from the relative importance
analysis [41]. Four studies provided level preference
weight graphs but no values, making it impossible to cal-
culate relative attribute importance [34, 38, 51, 54]. The
authors of these studies were contacted, but only one
replied whereby the relative importance could be calcu-
lated [54]. Five additional studies were excluded because
the methods of calculating relative importance were not
clearly stated and not reproducible [37, 46, 49, 53, 55]. The
levels chosen for similar attributes (e.g. progression-free
survival in months, certain adverse effects such as diar-
rhoea or fatigue) were very diverse across studies.
An overview of the relative importance scores per study
is included in supplementary online appendix D. Figure 3
shows the number of times a class of attributes was the
most important. The importance of an attribute was eval-
uated by comparing the relative importance scores of all
attributes within a study; the attribute with the highest
relative importance score was considered the most
important.
The analysis shows that an outcome attribute was con-
sidered the most important in 14 of the 19 studies (effec-
tiveness nine times, adverse effects four times, quality of life
one time), followed by cost attributes in three studies and
process attributes in two studies (mode of administration one
time and others one time). The analysis further shows that
process attributes were the most important only when no
outcome or cost attributes were included. The second most
important attributes were also mainly outcome related (14
times), followed by process-related ones (five times).
3.4.4 Mean Relative Importance
Comparison of the mean relative importance of an attribute
class indicates that outcome attributes have the highest
mean relative importance (37%) in comparison with pro-
cess (33%) and cost (33%).
4 Discussion
This systematic review of DCEs focusing on cancer treat-
ment preferences suggests that the number of DCEs has
been constant over recent years (2010–2016), with an
average of four publications per year. In contrast, the
average number of all DCEs in healthcare rose continu-
ously from a mean of three per year (1990–2000) to 14
(2001–2008) to 45 (2009–2012) [12, 22]. Most of the
studies investigated the preferences of adults at risk of
cancer or with treatment experience; however, there are
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also studies comparing patient’s preferences with those of
healthcare providers or carers. For the purposes of our
study, these latter studies have been analysed only
regarding the preferences of patients.
Our review identified a number of shortcomings of
current practice with regard to DCE applications in cancer
treatment. First, despite growing awareness of the impor-
tance of patient involvement and research on patient
preference, less than half of the cases (36%) carry out
attribute identification and selection in cooperation with the
patient. The majority of studies combined methods of
attribute identification, reporting most often literature
reviews (78%) and inclusion of professionals (71%).
Excluding patients from attribute identification and selec-
tion might introduce omitted variable bias and might
therefore lead to biased results on patients’ preferences,
since literature and professionals might deem different
attributes important for inclusion in the analysis. Although
we acknowledge that every research question does not
require starting with patient input, it is often important to
include patients at some point in time in attribute identi-
fication or selection, in refining attribute labelling and
framing, or to pre-test the survey instrument on patients.
Discrepancies between the preferences of professionals and
patients have been reported by Thrumurthy et al. [50], who
found differences in preferences between patients and
doctors regarding mortality and quality of life. Also, Regier
et al. [37] found that the importance ranking of effective-
ness and adverse effect attributes differed between parents
and healthcare professionals. Parents placed higher
importance on the chance of infection, while healthcare
professionals placed higher importance on chance of death
[37]. Methods for preventing this type of bias are linked to
the inclusion of patients in the process of attribute identi-
fication and selection and might be achieved through
patient focus groups or patient interviews. In addition, pre-
tests or pilot questionnaires could be used to increase the
clarity of questions and the comprehensiveness of attri-
butes relevant to patients.
A second potential issue is the administration of pref-
erence surveys. This review found that only 18% of the
studies made use of an interviewer-led survey. To improve
the data quality, the ISPOR guideline by Bridges et al. [8]
suggests that interviewer-led administration of the survey
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Fig. 2 Number of times an attribute class was used in all discrete choice experiments of cancer treatment and number of times an attribute class
















































































Fig. 3 Number of times an attribute class was the most important
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can recognize that more explanation is needed, can more
fully explain the task and can answer questions (without
leading the respondent). Interviewer-led administration,
however, may suffer from limitations such as high financial
and time expenses. Also, poorly trained interviewers might
lead respondents or provide different information to dif-
ferent respondents, which could result in worse data quality
than a self-administered survey. We therefore recommend
that surveys be adequately piloted and assessed before use
and that the mode of administration in each specific study
setting and study population should be individually deci-
ded. Some populations might require more personal sup-
port than others. On the other hand, large samples are
sometimes required and it might not be feasible to do
interviewer-administered surveys.
Third, we did not assess the recruitment and sampling
process of each study. It is, however, important that studies
report on these processes in sufficient detail to allow for
further analysis in case of a high proportion of non-re-
sponse in a DCE. High non-response could, for example,
indicate problems with getting access to the survey or with
the survey itself (e.g. being too comprehensive, compli-
cated, etc.).
Fourth, the number of included attributes varies across
studies; this review found that there is no clear trend or
standard regarding the amount of attributes to include,
which is in line with other reviews [12]. Fifth, when
looking at attribute labelling within DCEs, several incon-
sistencies have been highlighted. Terms used within the
reporting vary partially in comparison with terms used
within choice tasks. This inconsistency might cause prob-
lems with data interpretation based on published results.
Overall, the quality of reporting in DCEs was accept-
able, but there is room for improvement. Even after the
ISPOR guideline was implemented in 2011 [8], only 40%
of studies achieved a score of 4 on the PREFS checklist and
only one study achieved a score of 5 on the 5-point scale.
For example, with one exception, all studies ranked an
unacceptable score on the reporting of differences between
responders and non-responders, which might lead to a non-
response bias. Also, about half of the studies excluded
some responders from the analysis but did not investigate
the impact of these exclusions on study results. The most
commonly noted reasons were that responders failed the
comprehension test or did not answer enough choice tasks.
Instead of excluding these respondents from the analyses, it
would be interesting to understand why they, for example,
failed comprehension questions or did not complete the
survey, and to conduct sensitivity analysis on how their
ex-/inclusion might impact study results. A respondent
could have simply misinterpreted the test question but still
have fully understood the remaining DCE questions.
Our review suggests that a similar number of studies
included both outcome and process attributes; however,
more attributes regarding treatment outcomes than treatment
process were included. Our review suggests that most
attribute levels (78%) are significant and thus important for
patients. Based on the number of times that an attribute was
said to be the most important, one may conclude that out-
come attributes are the most important to patients. In this
context one should keep in mind that attribute importance
based on level ranges is always conditional on the levels
chosen. Attribute importance may differ across studies,
depending on the level selection of the same attribute in
different studies [5]. For example, we included one study in
metastatic breast cancer patients in this review that coded
the adverse effect attribute ‘hair loss’ into the categories 0,
48 and 94% chance of losing most or all of your hair [46],
while in another study in the same indication this attribute
was coded as none/not noticeable hair loss versus obvious
hair loss [44]. The large level range in the first study and the
rather vague/weak level definition in the second one might
have caused this attribute to rank as more important in the
first study (hair loss ranked first before, for example, fatigue,
ranked third, and diarrhoea, ranked sixth) and much less
important in the second study (hair loss ranked sixth, fatigue
ranked fifth and diarrhoea second). The second-ranking
attribute diarrhoea in this study, on the other hand, was
coded with levels from ‘2 stools or less per day’ to an
extreme level of ‘being unable to leave the house’ [44]
compared with a much less extreme coding of levels in the
first study [46] (i.e. having a 0, 5 or 15% chance of diar-
rhoea), where this attribute ranked only sixth. Also,
including separate attributes for a specific type of adverse
effect, its severity and frequency might generate much more
detailed results than if one adverse effect attribute combines
these dimensions in a single attribute, as can be seen by
comparing the studies by Miller et al. [39] and Smith et al.
[41]. Overall, the attribute and the attribute level choice
across studies included in this review was very diverse and a
comparison across studies was therefore difficult. Excluding/
including specific attributes in a DCE further impacts the
preference for the remaining attributes, which makes com-
parisons even more difficult to perform.
Our study showed that while an intervention’s effec-
tiveness and the prevention of adverse effects were usually
most preferred by patients, process and cost attributes were
also of, though of lesser, importance. Process and cost
attributes may be less important relative to effectiveness
attributes, but may still be important when it comes to real
life (not only hypothetical) treatment choices or, for
example, when it comes to decisions between treatment
options where treatment effectiveness and adverse effects
do not differ significantly.
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Cost was included in only one-third of the studies, and
especially in countries where health insurance is not obli-
gatory (60%) and patients have a higher chance of paying
costs out of pocket. Including a cost attribute in oncology
studies could be challenging since the cost of cancer drugs
could be extremely high. In addition to health insurance,
there are financial aid programmes for patients through
hospitals, drug companies and patient groups, and patients
often end up paying very different amounts for the same
drug. If patients can’t afford any of the costs in the ranges
offered in a DCE, then they could either ignore the attribute
or dominate on cost. Although cost is certainly very
important in treatment choice and adherence, including
costs in a DCE as an attribute does not always work and
more research could focus on how to estimate the impact of
cost when costs are so high many patients can’t afford
them.
Although this review followed best practices in sys-
tematic reviews, it has some limitations. First, the PREFS
checklist might not be comprehensive enough to assess all
relevant aspects of (reporting) quality within DCEs. The
checklist is limited to five questions and misses several
important criteria that should be reported by DCE studies.
In order to include additional important (reporting) quality
aspects of DCEs in the analysis, we combined the PREFS
checklist with aspects of the ISPOR checklist published by
Bridges and colleagues [8]. While we assessed the report-
ing of data quality regarding these items, our study does
not comprehensively address the potential limitations of
study quality, which might, for example, have been caused
by limited sample sizes or other methodological problems
with data analysis.
Second, this review focuses on cancer treatment attri-
butes; therefore, study results cannot be generalised to
cancer screening or treatment of differing diseases. Third,
the review could not include all studies in the analysis of
relative importance. Based on the range method, calcula-
tion of relative importance could be reproduced in about
70% of the studies, including one that was calculated after
the first author, upon request, provided the preference
weights. It was apparent that various studies lacked trans-
parency in the statistical analysis of DCE findings. Some of
the studies where the range method was not applied used
other methods to assess relative attribute importance,
among them the comparative willingness-to-pay for attri-
butes or just using the highest estimated level coefficient as
the weight for that attribute. Further research on patients’
preferences should explore the range of methods used in
DCEs to assess attribute importance and their potential
strengths and weaknesses. The range method proposed by
the ISPOR Conjoint Analysis Good Research Practices
Task Force may be the most often used, but it is not the
only method to assess attribute importance [29]. Finally,
this review included only full articles already published
and did not include conference protocols.
This research could provide valuable information for
clinical and policy decision-making as it provides infor-
mation about actual patient preferences. Involving patients
in decision-making might improve adherence to medica-
tion and therefore lead to greater efficiency. Moreover, this
review could guide further research in cancer preference
studies, as it provides an overview and insight into the
shortcomings of current practices in DCEs regarding can-
cer treatment.
5 Conclusion
In this systematic review of DCEs conducted to investigate
patients’ preferences for cancer treatment, we observed that
outcome attributes regarding effectiveness and adverse
effects are most often included within DCEs, and are often
considered the most important by patients. Process and cost
attributes, in contrast, are included less often but are still of
importance in most studies. Clinicians and decision makers
should be aware that patients value not only the outcome
but also process and cost attributes, and aligning care with
the patients’ preferences could lead to improved adherence
to treatment and therefore greater efficiency.
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